A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
暂无分享,去创建一个
P. Rouanet | P. Fumoleau | J. Chatal | M. Mahé | M. Fabbro | P. Chauvot | J. Classe | J. Guastalla | P. Faurous | L. Chetanoud | Lucienne Chetanoud
[1] E. Seregni,et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. , 1995, European journal of cancer.
[2] H. Haisma,et al. Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors. , 1988, American journal of obstetrics and gynecology.
[3] V. Zurawski,et al. Intraperitoneal radiolabeled OC125 in patients with advanced ovarian cancer , 1990 .
[4] J. Schlom,et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. , 1997, Gynecologic oncology.
[5] W. Creasman,et al. THE PROGNOSTIC VALUE OF PERITONEAL CYTOLOGY IN GYNECOLOGIC MALIGNANT DISEASE , 1972 .
[6] P. Rose,et al. Intraperitoneal therapy of ovarian cancer with Yttrium-90-labeled monoclonal antibodies : preliminary observations , 1991 .
[7] J. Chatal,et al. Use of multi‐cell spheroids of ovarian carcinoma as an intraperitoneal radio‐immunotherapy model: Uptake, retention kinetics and dosimetric evaluation , 1992, International journal of cancer.
[8] S. Stewart,et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] V. Zurawski,et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. , 1992, Gynecologic oncology.
[10] M. Slevin,et al. The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. , 1988, British Journal of Cancer.
[11] Johnson Wd. The cytological diagnosis of cancer in serous effusions. , 1966 .
[12] W. Johnson. The cytological diagnosis of cancer in serous effusions. , 1966, Acta cytologica.
[13] P. Fumoleau,et al. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas. , 1989, Cancer research.
[14] M. Sullivan,et al. Intraperitoneal radioimmunotherapy for ovarian cancer , 1989 .
[15] V. Abeler,et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole‐abdomen irradiation as adjuvant treatment of Ovarian cancer , 1992, Cancer.
[16] M. Slevin,et al. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. , 1987, Cancer research.
[17] J. Belinson,et al. False‐Negative Peritoneal Cytology in Metastatic Ovarian Carcinoma , 1986, Obstetrics and gynecology.
[18] A. Maraveyas,et al. Asbestos fibers in the colonic wall. , 1974, British Journal of Cancer.
[19] J. Neijt,et al. Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. , 1991, European journal of cancer.
[20] B. Piura,et al. [Second-look laparotomy in ovarian cancer]. , 1987, Harefuah.
[21] P. Saigo,et al. Peritoneal Cytology as an Indicator of Disease in Patients With Residual Ovarian Carcinoma , 1988, Obstetrics and gynecology.
[22] D. Snook,et al. Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. , 1989, International journal of radiation oncology, biology, physics.
[23] W. Mason,et al. Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions. , 1990, The British journal of cancer. Supplement.
[24] B. Atkinson,et al. Peritoneal washing cytology. Uses and diagnostic criteria in gynecologic neoplasms. , 1984, Acta cytologica.
[25] D. Alberts,et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.
[26] V. Torri,et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.